Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc.

0.98
EUR
-0.09
(-8.88%)
-1.43EPS
27.17MMarket Cap
Feb 26Next Earn

Total Valuation

EUR

As of June 30, 2026, Lisata Therapeutics, Inc. carries a market capitalization of 27.17M, placing it among publicly traded companies globally. Its enterprise value stands at 17.81M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap27.17M
Enterprise Value17.81M

Important Dates

Lisata Therapeutics, Inc.'s next confirmed earnings release is scheduled for February 26, 2027.

Earnings Date2/26/2027

Share Statistics

As of June 30, 2026, Lisata Therapeutics, Inc. has 9.12M shares outstanding.

Shares Outstanding9.12M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 303.72, and the price-to-book ratio stands at 3.77.

PS Ratio303.72
PB Ratio3.77
P/TBV Ratio3.77
P/FCF Ratio-2.46
P/OCF Ratio-2.46

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 203.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 17.81M versus a market cap of 27.17M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales203.49

Financial Position

As of June 30, 2026, Lisata Therapeutics, Inc. maintains a current ratio of 3.69, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.

Current Ratio3.69
Quick Ratio3.50

Financial Efficiency

EUR

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. posted a negative return on equity (ROE) of -99.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -80.81, reflecting losses generated across the asset base. The company generates approximately 3,933.93 in revenue per employee across its workforce of 22.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-99.89
Return on Assets (ROA)-80.81
Revenue Per Employee3,933.93
Employee Count22.25

Taxes

EUR

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. recorded an income tax benefit of -338,741.10 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -13.14M and -12.80M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-338,741.10

Stock Price Statistics

EUR

As of the close on November 17, 2026, Lisata Therapeutics, Inc.'s stock has declined approximately 46.72% over the past 52 weeks. The 50-day moving average sits at 1.12, while the 200-day moving average is 2.42.

52-Week Price Change-46.72%
50-Day Moving Average1.12
200-Day Moving Average2.42

Income Statement

EUR

Over the twelve months ended June 30, 2026, Lisata Therapeutics, Inc. generated 87,530.00 in revenue and converted that into -12.80M in net income, yielding earnings per share of -1.43. EBITDA reached -14.32M, while operating income came in at -14.38M.

Revenue87,530.00
Operating Income-14.38M
Pretax Income-13.14M
Net Income-12.80M
EBITDA-14.32M
EBIT-14.38M
Earnings Per Share (EPS)-1.43

Balance Sheet

EUR

These figures are as of June 30, 2026. Total book value stands at 7.22M, with working capital of 7.03M providing operational flexibility.

Cash & Cash Equivalents9.14M
Net Debt-9.14M
Equity (Book Value)7.22M
Book Value Per Share0.79
Working Capital7.03M

Cash Flow

EUR

Lisata Therapeutics, Inc. produced -10.79M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -10.79M - equivalent to -1.21 per share.

Operating Cash Flow-10.79M
Free Cash Flow-10.79M
FCF Per Share-1.21

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -16,427.00 and net profit margin of -14,621.00 provide insight into operational efficiency.

Operating Margin-16,427.00
Pretax Margin-15,008.00
Profit Margin-14,621.00
EBITDA Margin-16,363.00

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -40.57: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.47, meaning Lisata Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-2.47
FCF Yield-40.57

Stock Splits

Lisata Therapeutics, Inc.'s most recent stock split took place on September 15, 2022 with a 15:1 split ratio.

Last Split Date9/15/2022
Split Ratio15:1

Scores

As of June 30, 2026, Lisata Therapeutics, Inc. has an Altman Z-Score of -70.53, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-70.53